Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Sitagliptin Phosphate (Anhydrous) API

Product
  • Categoría Terapéutica Anti-diabético

  • Número CAS

    654671-77-9

  • Tecnología del API

    Sintética

  • Forma de Dosificación

    Sólidos Orales

  • Estado de Desarrollo en Dr. Reddy’s

    Disponible

  • Presentación Regulatoria Disponible

    USDMF, DMF de Brasil, DMF de Canadá, DMF de Corea

Mechanism of Action


Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretinsGLP-1 and GIP, gastrointestinal hormones released in response to a meal. By preventing GLP-1 and GIP inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas. This drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent low blood sugar (hypoglycemia) which is seen with some other oral hypoglycemic agents.


Indication


JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Liraglutida

Anti-diabético

arrow

Glimepirida

Anti-diabético

arrow

Pioglitazona Clorhidrato

Anti-diabético

arrow

Linagliptina

Anti-diabético

arrow

Clorhidrato De Sitagliptina

Anti-diabético

arrow

Dapagliflozina (amorfa)

Anti-diabético

arrow

Semaglutide

Anti-diabético

arrow

Descargo de responsabilidad

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.